Skip to main content

Prevnar 20 FDA Approval History

Last updated by Judith Stewart, BPharm on May 2, 2023.

FDA Approved: Yes (First approved June 8, 2021)
Brand name: Prevnar 20
Generic name: pneumococcal 20-valent conjugate vaccine
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Pneumococcal Disease Prophylaxis

Prevnar 20 (pneumococcal 20-valent conjugate vaccine) is a vaccine used for the prevention of invasive pneumococcal disease and otitis media.

Development timeline for Prevnar 20

Apr 27, 2023Approval U.S. FDA Approves Prevnar 20, Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for Infants and Children
Jun  8, 2021Approval FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.